The Silent Pandemic: Antimicrobial Resistance

WHO has declared AMR as one of the top 10 global public health threats facing humanity. In this webinar, experts share current research trends in AMR, key considerations of the current AMR environment, and solutions to positively change the trajectory of AMR.

Register Free: https://www.appliedclinicaltrialsonline.com/act_w/silent-pandemic

Event Overview:

Often referred to as the ‘silent pandemic,’ antimicrobial resistance (AMR) was linked to approximately five million deaths worldwide in 2019, including 1.3 million directly attributable to bacterial AMR. Contributing to this issue, approximately 47 million unnecessary antibiotic prescriptions are prescribed in the U.S. each year, according to the IQVIA Institute for Human Data Science.

WHO has declared AMR as one of the top 10 global public health threats facing humanity. In this webinar, experts share current research trends in AMR, key considerations of the current AMR environment, and solutions to positively change the trajectory of AMR.

Three key take-aways:

• Historical perspective of AMR and why there is a need for change
• Key considerations for driving awareness, research, and thought leadership in AMR
• The implications of ignoring global antimicrobial resistance

Speakers:

Colin Brown, MD
Infectious Disease and Medical Microbiology Consultant
UK Health Security Agency

Colin Brown, MD is an infectious disease and medical microbiology consultant working at UK Health Security Agency on a portfolio of clinical and emerging infection, antimicrobial resistance, and global health. His time is currently split between treating patients with clinical infections (including high-consequence infectious diseases) at the Royal Free Hospital in London, working on domestic infection policy in healthcare-associated infection and antimicrobial resistance activities as deputy director of the HCAI/AMR division, and as interim director of clinical and emerging Infections.

Philippe Glaser
Research Director, Head of Ecology and Evolution of Antibiotic Resistance Unit
Institut Pasteur

Philippe Glaser, research director at the Institut Pasteur, is heading the Ecology and Evolution of Antibiotic Resistance Unit. He is an expert in bacterial genomics and evolution of antibiotic resistance. He is well known for his genomic-epidemiology studies of Group B Streptococcus both in humans and in animals.

Research expertise:
He has shown how the extensive use of tetracycline starting in the 1950s has been responsible for the replacement of the GBS population colonizing humans by few tetracycline resistant clones and to the emergence of neonatal GBS infection in the 1960s – 1970s both in Europe and in the US.

In collaboration with T. Naas at the Bicêtre hospital he is deciphering the evolution and antibiotic resistance of carbapenemase producing enterobacteriaceae (mainly E. coli and K. pneumoniae). Together with Belgium veterinarian he is characterizing the transmission of ß-lactam resistant E. coli across farms. He also collaborates with Lulla Opatowski on the modelling of the transmission of antibiotic resistant bacteria. He is co-coordinating with Paola Arimondo (IP) the AMR axis of the Institut Pasteur strategic plan.

Sharon Hughes
Senior Therapeutic Strategy Director, Infectious Disease and Vaccines
IQVIA
Sharon Hughes is a Senior Director of Therapeutic Strategy in Infectious Diseases and vaccines, with over 28 years in of industry experience spanning both research and solid disease forms development. She has a deep focus on respiratory infectious diseases and antimicrobial resistance. Hughes is a strategist with years of experience in complex studies, managing clinical trials, and developing therapeutic strategies around infectious diseases.

Jeff Spaeder, MD
Global Chief Medical and Science Officer
IQVIA

Jeffrey Spaeder, MD, is the chief medical and scientific officer for IQVIA. In this role, he is the lead medical and scientific expert and is involved with the company’s oversight of scientific integrity, governance of early-phase development, quality assurance, and bioethics. Spaeder has more than 25 years of medical and research experience; and since 2005, he has worked in the life sciences industry. He also was a cardiologist on the faculty of Johns Hopkins University School of Medicine.

Register Free: https://www.appliedclinicaltrialsonline.com/act_w/silent-pandemic